MarginsXMarginsX
Home › Markets › Health Care › MRVI

Maravai LifeSciences Holdings Inc. (MRVI)

MRVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.40
-1.86% on the day
Market cap
$1.9B
Small cap
Revenue · 2025
$185.7M
-28.3% on 2024
Net income · 2025
-$130.8M
-70.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1823239/000182323926000011/0001823239-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMRVI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001823239
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$185.7M
Net income-$130.8M
Operating income-$215.3M
Net margin-70.4%
Operating margin-115.9%
Revenue growth-28.3%
Cash$216.9M
Total assets$770.6M
P/E (computed)Net income was not positive
P/S (computed)10.4×

Warning signs

Cash runway
172.0 months
$73.0M cash at September 30, 2026
Share count, 1 year
+1.7%
2025-10-31 to 2026-10-29
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$1.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$73.0M cash; operating cash flow -$1.3M a quarter.Report 2026-09-30
Shares outstanding259,938,547 (2026-10-29); 255,706,831 a year earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Diego, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-07-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.9M, sold $254K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$45.9M-$13.8M$5.0M$73.0M$147.2M$213.0M10-Q 2026-11-05
Q2 2026
2026-06-30
$51.4M-$12.4M$4.0M$70.1M$147.1M$208.8M10-Q 2026-08-07
Q1 2026
2026-03-31
$65.8M-$3.7M$8.7M$165.9M$241.0M$204.7M10-Q 2026-05-08
Q4 2025
2025-12-31
$49.9M-$35.7M-$22.8M$216.9M$291.8M$185.7M10-K 2026-02-26
Q3 2025
2025-09-30
$41.6M-$25.6M-$15.2M$243.6M$292.8M$192.4M10-Q 2026-11-05
Q2 2025
2025-06-30
$47.4M-$39.6M-$10.3M$269.9M$293.9M$219.8M10-Q 2026-08-07
Q1 2025
2025-03-31
$46.9M-$29.9M-$9.4M$285.1M$294.9M$241.9M10-Q 2026-05-08
Q4 2024
2024-12-31
$56.6M-$25.9M-$14.6M$322.4M$295.9M$259.2M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42021-09-13
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 426 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.3%
1 month+15.5%
3 months+30.4%
Year to date+132.0%
1 year+132.0%
From 52-week high-16.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
TRVITrevi Therapeutics Inc.$13.29-2.64%$1.9B
ZBIOZenas BioPharma Inc.$27.93-0.29%$1.9B
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
SEPNSepterna Inc.$41.67-2.18%$2.0B
ETONEton Pharmaceuticals Inc.$63.88-0.08%$1.8B
ZYMEZymeworks Inc.$26.45+0.80%$1.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier